Global Anthrax Therapeutics Market 2019-2023

Want to get a preview about how you can gain valuable insights from Technavio’s market research report? Check out the latest facts about the anthrax therapeutics industry

The global anthrax therapeutics market is expected to grow at a CAGR of more than 8% during the forecast period

Anthrax treatment industry growth is expected to accelerate over the next five years, driven by development of novel therapies for treatment of anthrax. Growing threat of exposure to among the civilian population and military forces has led to the development of new therapies for anthrax treatment, which will make a positive impact on the growth of the global anthrax market. Institutes such as University of California are conducting research to treat late-stage anthrax infections, which have shown favorable results. Technavio’s anthrax treatment industry analysis reveals promising markets around the world.

Get a free sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

The Americas dominated the anthrax therapeutics market by region

The global anthrax treatment market was dominated by the Americas with almost 89% of the global market share, followed by EMEA and APAC. In addition, the Americas will drive 81% of the growth for the global anthrax treatment industry, while EMEA and APAC are also predicted to contribute significantly to the incremental growth in the forecast period. The global anthrax treatment market will witness EMEA region registering the fastest rate of growth during the forecast period, while APAC will generate a higher CAGR than the Americas.

Bayer, Elusys Therapeutics, and Emergent BioSolutions are some of leading anthrax vaccine manufacturers

The global anthrax treatment market is forecasted to remain reasonably fragmented with the emergence of many international and regional anthrax vaccine companies who make drugs for the treatment of anthrax. Researchers are using a new approach called functional genomics to identify and study Bacillus anthracis proteins involved in conferring virulence to the bacterium, as the anthrax proteins’ identification would make possible the development of new generation anthrax vaccine candidates. Many established anthrax drug manufacturers are vying for their share of the global anthrax treatment market, and the new players must differentiate themselves to gain vital traction over their peers.

This report offers a complete analysis of several anthrax vaccine companies, including:

• Bayer
• Elusys Therapeutics
• Emergent BioSolutions

We can help! Our analysts can customize this report to meet your requirements. Get in touch